A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.
Melanoma (Excluding Uveal Melanoma)|Cervical Carcinoma|Pancreatic Carcinoma|Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Cancer|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced Solid Tumors|Undifferentiated Pleomorphic Sarcoma
BIOLOGICAL: XmAb®23104|BIOLOGICAL: Yervoy® (ipilimumab)
Treatment-related adverse events as assessed by CTCAE v4.03, Safety and tolerability, 56 Days
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.